Bioventus Inc (BVS)
11.24
+0.11
(+0.99%)
USD |
NASDAQ |
Nov 15, 16:00
11.23
-0.01
(-0.09%)
After-Hours: 20:00
Bioventus Research and Development Expense (TTM): 13.66M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.66M |
| June 30, 2024 | 12.86M |
| March 31, 2024 | 12.27M |
| December 31, 2023 | 13.45M |
| September 30, 2023 | 16.13M |
| June 30, 2023 | 17.73M |
| March 31, 2023 | 20.70M |
| December 31, 2022 | 23.85M |
| September 30, 2022 | 25.01M |
| June 30, 2022 | 26.55M |
| Date | Value |
|---|---|
| March 31, 2022 | 25.02M |
| December 31, 2021 | 19.04M |
| September 30, 2021 | 14.83M |
| June 30, 2021 | 12.24M |
| March 31, 2021 | 10.00M |
| December 31, 2020 | 11.20M |
| September 30, 2020 | 11.46M |
| June 30, 2020 | 11.60M |
| March 31, 2020 | 11.97M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.00M
Minimum
Mar 2021
26.55M
Maximum
Jun 2022
16.29M
Average
13.66M
Median
Sep 2024
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp | 1.519B |
| Insulet Corp | 201.00M |
| Perspective Therapeutics Inc | 28.53M |
| Xtant Medical Holdings Inc | 2.145M |
| Catheter Precision Inc | 0.219M |